Key result
Icosapent ethyl substantially reduces major CV events in statin-treated patients in REDUCE-IT.
Answers are grounded in this paper and cite their sources.
BACKGROUND: REDUCE-IT was a multinational, double-blind trial that randomized 8179 statin-treated patients with controlled low-density lipoprotein cholesterol and moderately elevated triglycerides to icosapent ethyl (IPE) or placebo. IPE was associated with a substantial reduction in the primary composite endpoint of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina requiring hospitalization. Since the original publication of the trial, there have been a myriad of additional analyses confirming the benefit of IPE in various patient groups. Our objectives in this review are to summarize the key findings of the REDUCE-IT trial and its subsequent analyses as well as to call for the reevaluation and expansion of current guidelines to incorporate IPE as a therapy for patients at elevated cardiovascular risk with mild or moderate hypertriglyceridemia.
No takes yet. Share an insight, caveat, or question.
Gaba et al. (2022) conducted a review in Elevated cardiovascular risk with mild or moderate hypertriglyceridemia (n=8,179). Icosapent ethyl (IPE) vs. Placebo was evaluated on Composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina requiring hospitalization. Icosapent ethyl substantially reduced the composite of CV death, nonfatal MI, nonfatal stroke, revascularization, or unstable angina in 8,179 statin-treated patients in REDUCE-IT.
Synapse has enriched 10 related papers. Consider them for comparative context: